Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for SAPHO Syndrome (Single-Arm, Open-Label)
ChiCTR2500108339Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ivarmacitinib in SAPHO syndrome (SAPHO), sponsored by First Hospital of China Medical University. Primary endpoints: Erythrocyte sedimentation rate, C-reactive protein and 9 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
SAPHO syndrome (SAPHO)
Beyond the preview
Go deeper on ChiCTR2500108339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108339.